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Abstract: Cyclodextrin polymers have high applicability in pharmaceutical formulations due to
better biocompatibility, solubility enhancement, loading capacity and controlled drug release than
their parent, cyclodextrins. The cytotoxicity and cell uptake of new cationic beta-cyclodextrin
monomers and polymers were evaluated as suitable materials for nasal formulations and their
protective effects on cells exposed to hydrogen peroxide were studied. PC12 and CACO-2 cells were
selected as the neuronal- and epithelial-type cells, respectively, to mimic the structure of respiratory
and olfactory epithelia of the nasal cavity. All cationic beta-cyclodextrin polymers tested showed
dose- and time-dependent toxicity; nevertheless, at 5 µM concentration and 60 min of exposure,
the quaternary-ammonium-beta-cyclodextrin soluble polymer could be recognized as nontoxic.
Based on these results, a fluorescently labelled quaternary-ammonium-beta-cyclodextrin monomer
and polymer were selected for uptake studies in CACO-2 cells. The monomeric and polymeric
beta-cyclodextrins were internalized in the cytoplasm of CACO-2 cells; the cationic monomer showed
higher permeability than the hydroxypropyl-beta-cyclodextrin, employed as comparison. Therefore,
these cationic beta-cyclodextrins showed potential as excipients able to improve the nasal absorption
of drugs. Furthermore, amino-beta-cyclodextrin and beta-cyclodextrin soluble polymers were able to
reduce oxidative damage in PC12 and CACO-2 cells and thus could be studied as bioactive carriers
or potential drugs for cell protection against oxidative stress.
Keywords: cationic cyclodextrin; cyclodextrin polymer; epichlorohydrin cross-linker; nasal delivery;
cytotoxicity; cell uptake
1. Introduction
Cyclodextrins (CDs) are very interesting excipients widely used in the pharmaceutical field due
to their peculiar properties. CDs are cyclic oligosaccharides, formed of α-D-glucopyranose units, with
a characteristic truncated cone shape having a hydrophilic outer surface and hydrophobic interior
cavity [1]. Therefore, CDs are able to entrap hydrophobic drugs in their cavities forming an inclusion
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complex, which favours drug dissolution in the aqueous phase, protects the drug from chemical
and enzymatic degradation and limits drug toxic effects [1,2]. Moreover, CDs act as penetration
enhancers and this property, in addition to the increased water solubility, leads to an improvement of
the bioavailability of drugs. The ability to enhance drug crossing through biological barriers is in part
due to interactions of CDs with lipid components of the membrane that induce a perturbation in the
fluidity and permeability [3].
Starting from native CDs (named α-CD, β-CD and γ-CD), more than 1500 CD derivatives have
been synthetized in order to improve their solubility and minimize toxicity [4]. Among the class of
β-cyclodextrin derivatives, (2-hydroxypropyl) beta-cyclodextrin (HP) is an approved pharmaceutical
excipient and its monograph has been published in both the European Pharmacopoeia and United
States Pharmacopoeia [5]. HP is recognized also as an active pharmaceutical ingredient and received
the orphan drug designation for the treatment of Niemann–Pick disease from the US Food and Drug
Administration (FDA) and the European Medicines Agency (EMA) [5–8]. Moreover, HP is able to
provide protection against neurotoxicity induced by β-amyloid, and therefore useful in the treatment
of Alzheimer’s disease [8–10]. HP and other CD derivatives showed a potential therapeutic use in
neurodegenerative diseases, stroke, neuro-infections and brain tumors [4,11].
CDs and their derivatives have also been polycondensed with a cross-linking agent, such as
epichlorohydrin, to obtain polymeric networks with better biocompatibility and solubility enhancement
than parent CDs as well as superior loading capacity and controlled drug release [12,13]. Cyclodextrin
polymers (CDPs) are high-molecular-weight compounds, they can be either soluble or insoluble in
water, and be found as positively or negatively charged or nonionic in nature [13]. Charged soluble
CDPs possess special complexing and solubilizing ability due to ionic interactions with ionic drugs [13]
such as insulin [14], DNA [15] and siRNA [16] and, thus, have been proposed as drug or gene carrier
systems. Nevertheless, CDPs have been studied only for oral and topical delivery [13].
On the basis of these assumptions, the aims of this work were to evaluate the cytotoxicity and
biocompatibility of cationic beta-cyclodextrin monomers and polymers and to explore their applicability
in nasal formulations. The positively charged beta-cyclodextrins could be advantageously used to
increase the residence time of formulations in the nasal cavity due to the ionic interactions with the
negative charges of mucus [17]. The influence of molecular weight and charge of CDPs on cell viability
was also investigated. In particular, the in vitro toxicity of cationic CDPs was evaluated and compared
to that of parent cyclodextrin and HPCD, selected as standard. CACO-2 and PC12 cells were chosen
as model of epithelial and neuronlike phenotypes, respectively to predict the effect of the cationic
beta-cyclodextrins in respiratory and olfactory mucosa of the nasal cavity [18]. By using fluorescently
labelled beta-cyclodextrins, uptake and permeation studies were performed.
Finally, in order to find a potential therapeutic activity of these compounds, the protective effects
against oxidative stress on cells exposed to hydrogen peroxide were evaluated.
2. Materials and Methods
2.1. Materials
Dulbecco’s modified Eagle’s medium (DMEM/F12, HEPES, no phenol red), fetal bovine
serum (FBS), horse serum (HS), streptomycin/penicillin, nonessential amino-acids, L-glutamine
and trypsin were purchased from Life Technologies Italia (Monza, Italy). Hydrogen peroxide
(H2O2, 30%), 3-(4,5-Dimethyl-thiazol-2-yl)-2,5,diphenyltetrazoliumbromide (MTT, 97.5%), rhodamine
B isothiocyanate, paraformaldehyde solution (adjusted to pH 7.4) solution, Hank’s salt (HBSS)
solution, 3-(4,5-Dimethyl-thiazol-2-yl)-2,5,diphenyltetrazoliumbromide triton X-100 were acquired
from Sigma-Aldrich (Milan, Italy) Beta-cyclodextrins (fluorescent or not) were from CycloLab Ltd.
(Budapest, Hungary).
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2.2. Beta-Cyclodextrins
Beta-cyclodextrin derivatives were produced and characterized by CycloLab as follows—
(2-hydroxy-3-N,N,N-trimethylamino)propyl-beta-cyclodextrin chloride (QA), quaternary- ammonium-
beta-cyclodextrin soluble polymer crosslinked with epichlorohydrin (QAPS) and quaternary
ammonium-6-deoxy-6-((5/6)-rhodaminylthioureido)- (2-Hydroxy-3-N,N,N-trimethylamino)-beta-
cyclodextrin (RBITC-QA) were obtained by solubilizing in alkaline conditions native beta-cyclodextrin,
beta-cyclodextrin soluble polymer and 6-deoxy-6-((5/6)-rhodaminylthioureido)-beta-cyclodextrin,
respectively, and by alkylating the reaction mixtures with glycidyltrimethylammonium chloride
for 12 h at room temperature. Extensive dialysis by using a low cut-off (100–500 Da) dialysis
membrane and freeze drying yielded the corresponding positively charged quaternary ammonium
CD compounds. Quaternary-ammonium-rhodamine-labelled beta-cyclodextrin soluble polymer
crosslinked with epichlorohydrin (RBITC-QAPS) was synthesized as previously reported [19]. Heptakis
(6-deoxy-6-amino)-beta-cyclodextrin heptahydrochloride (HA) was prepared according to a previously
described procedure [20]. Beta-cyclodextrin soluble polymer crosslinked with epichlorohydrin
(PS), amino-beta-cyclodextrin soluble polymer crosslinked with epichlorohydrin (HAPS), rhodamine
labelled beta-cyclodextrin soluble polymer crosslinked with epichlorohydrin (RBITC-PS) were prepared
according to synthetic procedures previously described [21]. 2-Hydroxypropyl-beta-cyclodextrin (HP)
and 6-deoxy-6-((5/6)-rhodaminylthioureido)-hydroxypropyl-beta-cyclodextrin (RBITC-HP) can be
prepared according to the synthetic descriptions previously reported [22].
The main properties of CDs utilized in the study are reported in Table 1; further information of
analogue fluorescent cyclodextrins are shown in Table S1 (Supplementary Materials).
Table 1. Description of beta-cyclodextrin monomers and polymers studied in this work.
Cyclodextrin Code DS 1 MW 2 CLR 3 CD 4
Analogue
Fluorescent
Cyclodextrin
(2-Hydroxy-3-N,N,N-trimethyl
amino) propyl-beta-cyclodextrin chloride QA 3 1589.8 3 RBITC-QA
Quaternary-ammonium-beta-cyclodextrin
soluble polymer crosslinked with
epichlorohydrin
QAPS 2.2 40,000 ~11 2.2 RBITC-QAPS
Heptakis (6-deoxy-6-amino)-beta-cyclodextrin
heptahydrochloride HA - 1383.3 7
Soluble amino-beta-cyclodextrin polymer
crosslinked with epichlorohydrin HAPS 1 25,000 ~10 1
(2-Hydroxypropyl)-beta-cyclodextrin HP 4.5 1400 RBITC-HP
Soluble β-cyclodextrin polymer crosslinked
with epichlorohydrin PS - 92,000 ~11 RBITC-PS
1 DS: Average Degree of Substitution; 2 MW: Average Molecular Weight (g/mol); 3 CLR: Cross-Linking Ratio (mol
epichlorohydrin /mol CD); 4 CD: Cationic Density (cationic groups per cyclodextrin unit).
In Figures S1 and S2 (Supplementary Materials), cartoon representations for the CD monomers
and polymers investigated in the study are shown.
2.3. Cell Culture and Cyclodextrins (CDs) Treatments
Rat pheochromocytoma-derived cell line (ATCCCRL-1721) PC12 cells (passage 12–25) were
cultured in atmosphere of 5% CO2/95% humidified air at 37 ◦C in 60 mm plastic culture plates in
Dulbecco’s modified Eagle’s medium (DMEM/F12) with 10% Horse Serum (HS), 5% Fetal Bovine Serum
(FBS) and 1% of penicillin/streptomycin. CACO-2 cells (European Collection of Cell Cultures (ECACC
UK) (passage 20–40) were maintained in tissue culture flask T75 in Dulbecco’s modified Eagle’s medium
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(DMEM) with 10% FBS, 1% nonessential amino acids, 1% L-glutamine and 1% penicillin–streptomycin
solution and maintained at 37 ◦C and 5% CO2. The experiments were performed in the cell lines
exposed to the different beta-cyclodextrin monomers and polymers (HP, QA, QAPS, HA, HAPS and
PS) at different concentrations and times of exposure.
2.4. In Vitro Cell Viability Studies
Caco-2 and PC12 cells were used as model of epithelial and neuronlike phenotypes,
respectively [16]. PC12 and CACO-2 cells were treated with the different concentrations of
beta-cyclodextrin monomers and polymers (0.5-1-2.5-5-10 µM) for 15, 30, 60 min and 24 h. At the
end of the experiments, the cell viability was assessed by the 3-(4,5-dimethyl-thiazol-2-yl)-2,5,
diphenyltetrazolium bromide (MTT) assay. Viable cells convert the soluble dye MTT to insoluble
formazan crystals. One mg/mL of MTT was added for each sample and incubated for 4 h at 37 ◦C.
MTT was removed, the cells rinsed with PBS and centrifuged, the supernatant discarded and the pellet
was dissolved in 2 mL of isopropanol. The absorbance values were detected at 578 nm (Diagnostic
Microplate Reader, BioTek UK, Swindon, United Kingdom). For the experiments, 1 × 105 cells/mL/well
were seeded in 24-well plates, performing all experiments in triplicate. The result was expressed as cell
viability in a percentage according to the following formula:
Cell viability (%) =
ODtreated cells
ODuntreated cells
× 100 (1)
where ODtreated cells was the optical density of cells treated with the beta-cyclodextrin monomers and
polymers and ODuntreated cells was the optical density of untreated cells used as control.
2.5. Uptake and Permeation Studies
2.5.1. Confocal Microscopy
CACO-2 cells (seeded on coverslip glass at the density 200,000 cells/mL/well) treated with
RBITC-HA, RBITC-PS and RBITC-QAPS (5 µM) for 30 min were analysed by confocal microscopy.
After the treatment, the cells were washed several times with PBS in order to eliminate the labelled
beta-cyclodextrins located outside the cells; then, CACO-2 cells were fixed with 4% paraformaldehyde
solution. The nuclei were stained with DAPI 2 µg/mL in PBS for 15 min and the coverslips were
sealed on microscope slides. Samples were observed by a confocal laser-scanning (Rhodamine B
isothiocyanate excitation: 568 nm HeNe laser; emission: 623 nm) microscope equipped with a Plan
Apochromatic 63x DIC oil objective (NA1.4) (LSM710; Zeiss, Oberkochen, Germany). The images were
analysed with the software Zen2008 Light Edition (Zeiss, Oberkochen, Germany).
2.5.2. Relative Beta-Cyclodextrins Uptake
CACO-2 cells were seeded in 96-well black plate at the density of 25,000 cells/well and exposed
to RBITC-HA, RBITC-PS and RBITC.QAPS (5 µM) dissolved in HBSS for 15, 30 and 60 min. At the
end of the incubation, the cells were washed 4 times with HBSS and the cell lysis was performed with
1% Triton X-100. The fluorescence intensity was measured by the microplate reader SpectraMax i3x
(Molecular Devices, LLC. San Jose, CA, USA) (rhodamine B isothiocyanate excitation: 568 nm and
emission: 623 nm).
2.5.3. Uptake and Transepithelial Permeability Evaluation in Cell Monolayers
CACO-2 cells were seeded at the density of 200,000 cells/0.5 mL in cell culture inserts for a
12-well plate pretreated with collagen (pore size 0.4 µm, growth area 1.12 cm2) and the basolateral
compartments were filled with 1.5 mL of complete medium. The cells were cultured for 21 days to obtain
differentiated cell monolayers and the medium was replaced twice per week. The monolayer integrity
was evaluated measuring the transepithelial electrical resistance (TEER, expressed in Ω cm−2) (EVOM
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Meter, World Precision Instruments, Germany GmbH, Friedberg, Germany) CACO-2 cell monolayers
were used for the experiments when TEER values were higher than 700 Ω cm−2. Before treatments,
the monolayers were washed twice with PBS, preincubated in HBSS for 20 min and then exposed
apically to the RBITC-HA, RBITC-PS and RBITC-QAPS (5 µM) in HBSS for 15, 30 and 60 min at 37 ◦C.
Samples derived from the basolateral compartments were collected for each exposure time and the
volumes replenished with HBSS. The monolayers were washed four times with HBSS and lysed with 1%
Triton-X100. The fluorescence intensity in the intracellular and in the corresponding basolateral samples
was measured by the microplate reader SpectraMax i3x (Molecular Devices, LLC., San Jose, CA, USA)
(Rhodamine B isothiocyanate excitation: 568 nm and emission: 623 nm). The obtained values were used
to calculate the apical to basolateral permeation rate across the monolayers measuring the apparent
permeability coefficients:
Papp = (dQ/dt) × (1/C0 × A) (2)
where Papp is the apparent permeability coefficient (cm/s), dQ/dt is the permeability rate of
beta-cyclodextrins (mol/s), C0 is the initial concentration of beta-cyclodextrins in the apical chamber
(mol/mL) and A is the surface area of the membrane (cm2).
2.6. Studies of Protective Effects
PC12 and CACO-2 cells were exposed to hydrogen peroxide (75 µM) in the presence of HP,
QA, QAPS, HA, NH2-PS and PS (0.5 µM) for 24 h. At the end of the experiments, the cell viability
was assessed by the 3-(4,5-dimethyl- thiazol-2-yl)-2,5, diphenyltetrazolium bromide (MTT) assay.
Viable cells convert the soluble dye MTT to insoluble formazan crystals. A total of 1 mg/mL of
MTT was added for each sample and incubated for 4 h at 37 ◦C. MTT was removed, the cells
rinsed with PBS and centrifuged, the supernatant discarded and the pellet was dissolved in 2 mL of
isopropanol. The absorbance values were detected at 578 nm (Diagnostic Microplate Reader, BioTek
UK, Swindon, United Kingdom). For the experiments, 1 × 105 cells/mL/well were seeded in 24-well
plates, performing all experiments in triplicate.
2.7. Statistical Analysis
All experiments were reported as mean values with 95% confidence intervals. Statistical
significance (control vs. experimental groups) was evaluated by One-Way ANOVA analysis of
variance test using Graph-Pad Prism 5.0 software (GraphPad Software, Inc, San Diego, CA, USA).
3. Results
3.1. In Vitro Cell Viability Studies
Figures 1 and 2 show the effects of HP, QA, QAPS, HA, HAPS and PS at different concentrations
and exposure times (30 and 60 min) on PC12 and CACO-2 cell viability, respectively. Almost all
beta-cyclodextrins tested at 30 and 60 min did not induced a significant decrease of cell viability
until the concentration of 5 µM in both cell lines without differences between the two time points.
Only QAPS and HAPS showed a slight decrease in cell viability at 30 and 60 min of treatment at the
highest concentration of 10 µM. HP, QA and QAPS did not show toxic effects on CACO-2 cells up to
5 µM concentration (Figure 2). On the basis of these data, the concentration of 5 µM of HP, QA and
QAPS was used in the following studies in CACO-2 cells.
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Figure 2. Effect of different concentrations (0.5–1–2.5–5–10 µM) of HP, QA, QAPS, HA, HAPS and
PS on CACO-2 cell viability at increasing times of exposure (30 and 60 min). Data are reported as
mean ± SD (n = 3). * p < 0.05 vs. Control (ANOVA test).
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Other experiments were performed at higher exposure times (24 h) as shown in Figure S3–S6 of
the Supplementary Material. In particular, at 24 h of exposure, QAPS showed lower toxicity in PC12
cells than CACO-2 cells at all concentrations.
3.2. Uptake Studies by Confocal Microscopy
The uptake study was performed using the fluorescent rhodamine-conjugated RBITC-HP,
RBITC-QA and RBITC-QAPS (5 µM, chosen on the basis of the cell viability data) to demonstrate
their internalization in CACO-2 cells after 30 min from treatments. The confocal microscopy analysis
(Figure 3) showed that all labelled beta-cyclodextrins tested (red) were able to enter in CACO-2 cells,
placing in close proximity to the nucleus (blue), but with different efficiency. In particular, the uptake
of the monomer RBITC-QA was higher than RBITC-HP and the polymer RBITC-QAPS.Pharmaceutics 2020, 12, x 8 of 14 
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Figure 3. Uptake analysis of the fluorescence of RBITC-HP, RBITC-QA and RBITC-QAPS (5 µM) in
CACO-2 cells by confocal microscopy after 30 min of exposure. The figure shows the internalization
by CACO-2 cells of the different labelled beta-cyclodextrins in comparison with untreated cells or
treated with rhodamine not conjugated (blue channel—nuclear stain; red channel—rhodamine alone or
conjugated with beta-cyclodextrins).
3.3. Relative Beta-Cyclodextrins Uptake
The beta-cyclodextrin absorption was also evaluated using RBITC-HP, RBITC-QA and
RBITC-QAPS (5 µM) at 15, 30 and 60 min of exposure in CACO-2 cells seeded in 96-multiwell plates
(Figure 4). The fluorescence intensity recorded in the cell lysates did not show any significant difference
between the samples at increasing time. In fact, the uptake expressed as relative beta-cyclodextrin
uptake percentage was around 38% for all samples.
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Figure 4. Relative beta-cyclodextrin uptake in CACO-2 cells. Evaluation of the intracellular fluores nce
in CACO-2 cells after exposure to RBITC-HP, RBITC-QA and RBITC-QAPS (5 µM) for 15, 30 and 60 min.
Data are reported as mean ± SD (n = 3). * p < 0.05 vs. rho-B 0.5 µM at 15, 30 and 60 min (ANOVA test).
3.4. Uptake and Transepithelial Permeability Evaluation in Cell Monolayers
To study the permeability in CACO-2 cell monolayers, the fluorescent RBITC-HP, RBITC-QA and
RBITC-QAPS (5 µM) were used at 30 min of exposure (Figure 5a). During the experiments, no changes
in monolayer integrity were recorded according to TEER values. The amount of beta-cyclodextrins
(%) was directly proportional to the fluorescence intensity. Figure 5a shows that the intracellular
fluorescence intensity (I) at 30 min follows this order—RBITC-QA (49%) > RBITC-QAPS (42%) >
RBITC-HP (36%). Moreover, in the basolateral chamber (BC), no significant difference was identified
between the fluorescence intensity of the different cyclodextrins. On the basis of this result, the
permeability of RBITC-QA in CACO-2 cell monolayers was studied also at 15 and 60 min of exposure.
As shown in Figure 5b, RBITC-QA was able to quickly cross the cell membrane and accumulate into
the cells within 15 min, after which the intracellular amount of RBITC-QA increased and reached the
maximum at 30 min.
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Figure 5. Evaluation of transepithelial permeability of RBITC-HP, RBITC-QA and RBITC-QAPS
(5 µM) in CACO-2 cell monolayers. (a) Amount of cyclodextrins accumulated into the cells and in the
basolateral compartment at 30 min. * p < 0.05 vs rho-B - I and BC; # p < 0.05 vs. RBITC-QA - I; § p < 0.05
vs. RBITC-QAPS - I (ANOVA test). (b) Amount of RBITC-QA accumulated into the cells and in the
basolateral compartment at 15, 30 and 60 min. * p < 0.05 vs. rho-B - I and BC; # p < 0.05 vs. 30 min - I
and 60 min - I (ANOVA test). Data are reported as mean ± SD (n = 3).
The Figure 6 shows the transepithelial permeability values of the studied beta-cyclodextrins.
The obtained data showed that transepithelial permeability of RBITC-QA at 30 min is higher than that
measured for RBITC-HP and RBITC-QAPS.
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Figure 6. Evaluation of transepithelial permeability of RBITC-HP, RBITC-QA and RBITC-QAPS in
CACO-2 cell monolayers. (a) The apparent permeability (Papp) values at 30 min. * p < 0.05 vs. rho-B;
# p < 0.05 vs. RBITC-QA; § p < 0.05 vs. RBITC-QAPS (ANOVA test). (b) The apparent permeability
(Papp) of RBITC-QA at 15, 30 and 60 min. * p < 0.05 vs rho-B (ANOVA test). Data are reported as
mean ± SD (n = 3).
3.5. Studies of Protective Effects
As shown in Figure 7, the protective effect of HP, QA, QAPS, HA, HAPS and PS (0.5 µM) in PC12
and CACO-2 cells exposed to hydrogen peroxide (75 µM) for 24 h was evaluated and compared. In the
presence of HAPS and PS, the H2O2-induced damage was reduced to 18% and 17% in PC12 cells,
respectively, and 12% and 14% in CACO-2 cells, respectively.
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cationic beta-cyclodextrin monomers and polymers and thus suggesting their use for nasal formulations.
All cationic beta-cyclodextrin polymers, QAPS and HAPS, show dose- and time-dependent toxicity;
nevertheless, at 5 µM concentration and 60 min of exposure, the cell viability value is about 80%
for QAPS and thus it could be recognized as nontoxic [24–26]. HAPS has low toxic effect at 5 µM
concentration and 60 min of exposition. The exposure time of 60 min is considered enough for nasal
excipients/drugs due to the fast nasal mucociliary clearance; mucociliary transit time in humans is
normally 12 to 15 min [27]. As expected, the in vitro cytotoxicity of cationic beta-cyclodextrin polymer
was higher than PS and respective monomers (HA and QA) and HP. These results are related to the
charge and density of charge of the macromolecules and their molecular weight. As reported by Fischer
and co-workers, the molecular weight as well as the cationic charge density affect the interaction with
the cell membranes and thus, the cell damage [28]. The positive charge of the macromolecules enables
the electrostatic interactions with the negatively charged components of the cell membrane, which
disturbs the membrane structure and function, and, consequently, the metabolic activity of cells [28,29].
It follows that the higher number of charges of the macromolecules determine a greater degree of
interaction and, thus, a higher damaging effect (HA versus QA; HAPS versus QAPS). The molecular
weight is correlated with the toxicity of polymers in respect to the monomers (QAPS versus QA;
HAPS versus HA). Moreover, the permanently charged macromolecules, containing the quaternary
ammonium groups (QA and QAPS), exhibit a lower toxicity than those with protonable primary and
secondary amines (HA and HAPS) [28,30].
Cell viability has been tested also after 24 h incubation time in order to predict the long-term
toxicity. The toxicity of HAPS is unchanged after 24 h treatment time, whereas that of QAPS increases
and is pronounced in PC12 compared with CACO-2 (p < 0.05). This behaviour is probably related to
the molecular weight. In fact, the cytotoxicity of cationic chains with a medium range of molecular
weight (1.7–3.9 × 104 g/mol) is related to the destabilization of the cellular membrane, whereas cationic
polymers with long chains (Mw > 3.9 × 104 g/mol) are more toxic in the intracellular space, but longer
time and repeated exposure are required [31].
Based on in vitro cytotoxicity, QAPS and QA were selected for uptake studies. Fluorescently
labelled HP (RBITC-HP) was tested as comparison. The endocytosis of fluorescently labelled random
methyl-beta-cyclodextrin, (2-hydroxypropyl)-beta-cyclodextrin and soluble beta-cyclodextrin polymer
cross-linked with epichlorohydrin has been already revealed [32,33]. CACO-2 cells were chosen
because they grow in culture as an adherent monolayer of epithelial cells compared to PC12 and
they are suitable for transport studies [34]. The uptake evaluated by confocal microscopy showed
that after 30 min, all monomeric and polymeric fluorescent beta-cyclodextrins were internalized in
the cytoplasm of CACO-2 cells with different efficiency. In fact, the RBITC-QA crossed biological
membranes better than the polymer RBITC-QAPS. These results were confirmed and quantified by
the experiments of transepithelial permeability on CACO-2 cell monolayers. In particular, RBITC-QA
showed higher transepithelial permeability than RBITC-HP and the polymer RBITC-QAPS. Whereas,
the uptake measured in 96-multiwell plates did not show differences between beta-cyclodextrins at
different concentrations and times of exposure; this effect was probably due to a limit in the sensitivity
of the method. The obtained data confirmed a good availability of QA and QAPS to cross biological
membranes and a valid uptake of these in the cell environment. It means that also QAPS as an excipient
can improve the nasal absorption of drugs by promoting the transport into the cells within 15 min.
This is an important property for nasal drug delivery systems to overcome the poor permeability of
nasal mucosa and the short absorption time available due to fast mucociliary clearance. The contact
time of drugs with the mucosa could be also increased by the electrostatic interactions between the
cationic beta-cyclodextrin and sialic acid resides of mucin.
The results obtained warrant further research on a possible intrinsic pharmacological action of
these cationic beta-cyclodextrins and to study their possible role as adjuvants in pharmacological
therapies or as active pharmaceutical ingredients. In this regard, the activity of the molecules on
oxidative stress induced by H2O2 was evaluated in both cell lines, PC12 and CACO-2—the protective
Pharmaceutics 2020, 12, 658 11 of 13
effect of the two polymers HAPS and PS was shown. The HAPS and PS reduced oxidative damage
in PC12 and CACO-2 cells. This new property is particularly interesting and gives a potential
antioxidant activity to HAPS and PS, which could be used in the prevention and/or treatment of
oxidative stress-related neurodegenerative diseases. If administered nasally, these cationic polymers
could directly reach the brain by nose to brain transport and perform this pharmacological activity.
Nevertheless, the mechanism that causes this antioxidant effect is unknown and therefore it is the
subject of further studies currently in progress.
5. Conclusions
The cytotoxicity and cell uptake studies indicated that cationic beta-cyclodextrins monomers and
polymers possess low toxicity, a good uptake and a different permeability index depending on the
density of charge and the molecular weight. In particular, QA and QAPS could be regarded as useful
nasal excipients able to improve the absorption of drugs. Moreover, the preliminary studies suggest
a potential protective effect against oxidative stress of HAPS and PS in both cell lines, supposing an
intrinsic action which needs to be deeply investigated.
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